Benzinga | Sep 16, 2021 08:41AM EDT

UBS Maintains Buy on Biogen, Lowers Price Target to $442

UBS analyst Colin Bristow maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $475 to $442.